Mode
Text Size
Log in / Sign up

Global GJB2 mutation prevalence in nonsyndromic hearing impairmentOne in four people with hearing loss carries a specific gene mutation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
GJB2 mutations occur in 25.9% of nonsyndromic hearing impairment cases globally, with prevalence varying by region, supporting targeted genetic screening.

This systematic review and meta-analysis synthesized data from 24 countries, encompassing 18,968 patients with nonsyndromic hearing impairment, to determine the global prevalence of GJB2 gene mutations. The primary analysis focused on the overall prevalence of GJB2 mutations and five hotspot variants, providing a comprehensive epidemiological overview for clinicians and genetic counselors.

The overall prevalence of GJB2 mutations was 25.9% (95% CI: 21.7-30.1%), indicating that approximately one in four patients with nonsyndromic hearing loss harbors a pathogenic variant in this gene. This finding underscores the significant role of GJB2 in the etiology of hereditary hearing impairment and supports its inclusion in targeted genetic testing panels.

Among the specific hotspot variants, c.235delC was the most common, with a prevalence of 15.2%, followed by c.35delG at 12.0%. Other notable variants included c.109G>A (7.6%), c.299_300delAT (3.1%), and c.176_191del16 (0.7%). These variants collectively account for a substantial proportion of GJB2-related hearing loss, informing the design of region-specific genetic screening strategies.

Regional analysis revealed significant geographic heterogeneity. The prevalence of GJB2 mutations was highest in the Middle East at 38.5%, suggesting a founder effect or population-specific genetic architecture. In contrast, the prevalence in Africa was 11.1%, highlighting the need for tailored diagnostic approaches based on ancestral background.

The study's practice relevance emphasizes supporting region-specific genetic screening to improve early diagnosis, counseling, and targeted interventions for hereditary hearing loss. For clinicians, these data can guide the selection of genetic tests and inform discussions with patients about the likelihood of identifying a GJB2 mutation.

Limitations of the meta-analysis include potential heterogeneity in study designs and diagnostic criteria across the included studies. The analysis did not assess the functional impact of each variant or correlate genotype with phenotype severity, which are important considerations for clinical management.

In conclusion, this meta-analysis provides robust estimates of GJB2 mutation prevalence in nonsyndromic hearing impairment, with clear regional variations. These findings support the integration of genetic testing into routine care for patients with hearing loss, particularly in regions with high prevalence, to facilitate early intervention and family counseling.

Imagine losing your hearing without any other health problems. This is called nonsyndromic hearing impairment. For many families, this diagnosis comes as a shock because the cause remains a mystery. Now, a new analysis of data from 18,968 patients across 24 countries offers a clearer picture. It shows that a specific genetic change is far more common than doctors previously thought. This finding changes how we talk about the cause of hearing loss and helps families understand their risks better.

The researchers looked at a gene called GJB2. This gene helps cells in the ear communicate. When it has certain mutations, hearing can be affected. The team analyzed data from people who had hearing loss but no other syndromes or health issues. They focused on six specific changes in this gene that are known to cause problems.

The results were striking. Overall, 25.9 percent of patients had one of these mutations. That means roughly one in four people with this type of hearing loss carries the genetic marker. Two specific changes were very common. The c.235delC mutation was found in 15.2 percent of cases. The c.35delG mutation was found in 12.0 percent of cases. Another change, c.109G > A, appeared in 7.6 percent of patients.

The study also highlighted how location matters. In the Middle East, the rate jumped to 38.5 percent. In Africa, it was 11.1 percent. These numbers show that the genetic cause of hearing loss is not the same everywhere. The specific mutations people carry depend heavily on where they live and their family history.

There were no safety concerns to report because this was a genetic analysis, not a drug trial. The researchers did not find any new risks. However, this is a single large study. It combines data from many places, but it still represents one snapshot in time. Doctors should not assume every patient has this mutation. Other genetic causes still exist.

This research supports region-specific genetic screening. If a family lives in an area where these mutations are common, testing for them makes sense. Early diagnosis helps with counseling and targeted interventions. Families can understand their specific risks and make informed choices. This knowledge brings clarity to a condition that has long been a mystery for many.

What this means for you:
One in four patients with nonsyndromic hearing loss has a common GJB2 mutation.

Study Details

Study typeMeta analysis
Sample sizen = 18,968
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Nonsyndromic hearing impairment (NSHI) is the most common type of inherited hearing loss. Mutations in GJB2, which encodes connexin 26, are a major cause worldwide, but their prevalence and variant distribution vary across populations. To systematically evaluate the global prevalence of GJB2 mutations and 5 hotspot variants (c.35delG, c.176_191del16, c.235delC, c.299_300delAT, and c.109G > A) in NSHI patients, and assess their diagnostic relevance. METHODS: A meta-analysis was conducted on studies published between January 2019 and June 2024 retrieved from PubMed, Scopus, Web of Science, and Cochrane Library. Only high-quality studies (Newcastle-Ottawa Scale ≥ 7) with molecular diagnostic data were included. Pooled prevalence, 95% confidence intervals, and heterogeneity (I2) were calculated. Subgroup and meta-regression analyses were performed according to geographic region. RESULTS: Fifty-one studies from 24 countries covering 18,968 patients with NSHI were included. The overall prevalence of GJB2 mutations was 25.9% (95% confidence intervals: 21.7-30.1%; I2 = 96%). The variant-specific rates included c.235delC (15.2%), c.35delG (12.0%), c.109G > A (7.6%), c.299_300delAT (3.1%), and c.176_191del16 (0.7%). The highest prevalence occurred in the Middle East (38.5%), whereas Africa had the lowest (11.1%). CONCLUSION: GJB2 mutations show marked geographic and ethnic variability in populations with NSHI. These findings support region-specific genetic screening to improve the early diagnosis, counseling, and targeted interventions for hereditary hearing loss.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.